Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Second patient dosed in phase I/II MARVEL-1 study of FLT-190 in Fabry disease

June 17, 2021

Positive interim data from phase I study of ALT-801 in overweight and obese volunteers

June 17, 2021

Novadip reports phase I data on first-generation autologous cell-based osteogenic product NVD-001

June 15, 2021

New mouse model recapitulates the pancreatic features of human MODY5

June 15, 2021

Lilly opens phase II trial of LY-3437943 in type 2 diabetes

June 14, 2021

Phase II proof-of-concept study of VX-864 in AATD meets primary endpoint

June 11, 2021

Yuhan Corp., Green Cross Corp. present new GLCT-1 inhibitors

June 11, 2021

First European CTA accepted for phase I/II study of INZ-701 in ABCC6 deficiency

June 10, 2021

Bayer patents prostaglandin E2 receptor EP3 subtype antagonists

June 10, 2021

Yuhan Corp. describes compositions including GDF15 variants

June 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.